1
Dec
2022

Alzheimer’s Debate, Nimbus to Challenge BMS, & a Microbiome First

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Protagonist Delivers, BMS Bargain Hunts, and Zealand Goes Major League
Biotech Legend Retires, Jazz Buys Glioma Drug, & FDA Shakeup
Bluebird Fire Sale, Regeneron’s Gene Therapy for Deafness, & Eikon Raises a Bundle
Defend Young Scientists